GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Phoenix Biotech Acquisition Corp (NAS:PBAX) » Definitions » Cash Ratio

Phoenix Biotech Acquisition (Phoenix Biotech Acquisition) Cash Ratio : 0.02 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Phoenix Biotech Acquisition Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Phoenix Biotech Acquisition's Cash Ratio for the quarter that ended in Sep. 2023 was 0.02.

Phoenix Biotech Acquisition has a Cash Ratio of 0.02. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Phoenix Biotech Acquisition's Cash Ratio or its related term are showing as below:

PBAX' s Cash Ratio Range Over the Past 10 Years
Min: 0.02   Med: 0.32   Max: 11.21
Current: 0.02

During the past 2 years, Phoenix Biotech Acquisition's highest Cash Ratio was 11.21. The lowest was 0.02. And the median was 0.32.

PBAX's Cash Ratio is not ranked
in the Diversified Financial Services industry.
Industry Median: 0.69 vs PBAX: 0.02

Phoenix Biotech Acquisition Cash Ratio Historical Data

The historical data trend for Phoenix Biotech Acquisition's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phoenix Biotech Acquisition Cash Ratio Chart

Phoenix Biotech Acquisition Annual Data
Trend Dec21 Dec22
Cash Ratio
11.21 0.02

Phoenix Biotech Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.58 0.02 0.05 0.02 0.02

Competitive Comparison of Phoenix Biotech Acquisition's Cash Ratio

For the Shell Companies subindustry, Phoenix Biotech Acquisition's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phoenix Biotech Acquisition's Cash Ratio Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Phoenix Biotech Acquisition's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Phoenix Biotech Acquisition's Cash Ratio falls into.



Phoenix Biotech Acquisition Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Phoenix Biotech Acquisition's Cash Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash Ratio (A: Dec. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.476/30.748
=0.02

Phoenix Biotech Acquisition's Cash Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash Ratio (Q: Sep. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.119/4.801
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Phoenix Biotech Acquisition  (NAS:PBAX) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Phoenix Biotech Acquisition Cash Ratio Related Terms

Thank you for viewing the detailed overview of Phoenix Biotech Acquisition's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Phoenix Biotech Acquisition (Phoenix Biotech Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
2201 Broadway, Suite 705, Oakland, CA, USA, 94612
Website
Phoenix Biotech Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company intends to pursue an acquisition opportunity in any business, industry, sector or geographical location, industries that complement management team's background, and to capitalize on the ability of management team to identify and acquire a business in the healthcare or healthcare related industries in the United States and Europe.
Executives
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Brian G Atwood director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kathleen Laporte director
Christopher B Ehrlich director, 10 percent owner, officer: CEO and and Secretary 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Douglas Fisher officer: President 587 PATROL RD, WOODSIDE CA 94062
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Phoenix Biotech Sponsor, Llc 10 percent owner 2001 MARKET STREET, SUITE 3400, PHILADELPHIA PA 19103